BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

348.60M

Vuru Grade

23.50/100

Current Price

$4.73
+0.02 (+0.42%)

Company Metrics

  • P/E 0
  • P/S 13.78
  • P/B 25.88
  • EPS -0.98
  • Cash ROIC -251.78%
  • Cash Ratio 0.80
  • Dividend 0 / 0%
  • Avg. Vol. 961,356.00
  • Shares 73.70M
  • Market Cap. 348.60M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Biotech news that matter for investors: BioCryst Pharmaceuticals, Inc. (NASDAQ ...
The Voice Registrar - 14 hours ago
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) share price declined to $4.71 each in the last trading day compared to a prev close of $4.76.
BioCryst Pharma (BCRX) Closes New $23M Senior Credit Facility with Midcap ... - StreetInsider.com
What Do Analysts Think Of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)? - Fiscal Standard
Here's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July
Motley Fool - Aug 11, 2016
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company primarily focused on small-molecule drugs that block enzymes associated with disease development, leaped 27% in July, according to data from S&P Global Market ...
Notable Analyst Views: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), 3D ... - Review Fortune
BioCryst Pharmaceuticals Inc. (BCRX) Insider Thomas R. Staab II Sells 14577 Shares - BBNS
BioCryst Pharmaceuticals Inc Realized Volatility Hits A Notable High
CML News - Sep 23, 2016
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) . We also look at broad measures of the S&P 500 and Nasdaq 100 ...
BioCryst Pharmaceuticals Inc. (BCRX) VP Alane P. Barnes Sells 8357 Shares
The Cerbat Gem - Sep 17, 2016
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) VP Alane P. Barnes sold 8,357 shares of BioCryst Pharmaceuticals stock in a transaction on Wednesday, September 14th.
Insider Selling: BioCryst Pharmaceuticals Inc. (BCRX) VP Sells 8357 Shares of ... - BBNS
What Analysts say about BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)?
Review Fortune - Aug 15, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) received a stock rating upgrade from Piper Jaffray on Aug-12-16. In a note to investors, the firm issued a Overweight rating an.
Price Target Analysis: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - News Oracle
Technical Glance At Healthcare Stocks: Immune Pharmaceuticals, Inc. (NASDAQ ... - TWN
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2016 Results ...
Seeking Alpha - Aug 5, 2016
Good day, ladies and gentlemen. Welcome to the BioCryst Second Quarter 2016 Conference Call. At this time, all participants are in a listen-only mode.
Intraday Active Biotech Stocks News: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ...
The Voice Registrar - Sep 23, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed at $4.76, up 0.07 points or 1.49 percent from prior closing price.
Brokers Update Target Prices On BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Fiscal Standard
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Updated Analyst Ratings
Review Fortune - Aug 12, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) up 25.75% for the past 5 days, is under coverage of 9 analysts who collectively assign a hold rating on stock.
Analyst Update: InvenSense Inc, BioCryst Pharmaceuticals, Inc., and Alibaba ... - Schaeffers Research (blog)
BioCryst Pharmaceuticals Inc. (BCRX) Stock Rating Upgraded by Piper Jaffray Cos. - BBNS
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) Given Consensus Recommendation of ...
BBNS - Sep 19, 2016
BioCryst Pharmaceuticals logo Shares of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) have earned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock.
Analysts Review: Alon USA Energy, Inc. (NYSE:ALJ), BioCryst Pharmaceuticals ... - Newburgh Press
Trending Stocks: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Arrowhead ... - Benchmark Monitor
BioCryst Pharmaceuticals Inc. (BCRX) VP Yarlagadda S. Babu Sells 30000 Shares
The Cerbat Gem - Aug 29, 2016
BioCryst Pharmaceuticals logo BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) VP Yarlagadda S. Babu sold 30,000 shares of the firm's stock in a transaction on Thursday, August 25th.
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX): A Play On The Zika Virus - Street Register